Literature DB >> 35155063

Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment.

Cathal J Hannan1,2,3, Daniel Lewis1,2, Claire O'Leary1,4, Carmine A Donofrio1,2, Dafydd G Evans5,6, Emma Stapleton7,8, Simon R Freeman7,8, Simon K Lloyd4,7,8, Scott A Rutherford2, Charlotte Hammerbeck-Ward2, David Brough4,9, Stuart M Allan4,9, David Coope1,2,4, Andrew T King1,2,3, Omar N Pathmanaban1,2,10.   

Abstract

Introduction  Vestibular schwannomas (VS) are histologically benign tumors arising from cranial nerve VIII. Far from a homogenous proliferation of Schwann cells, mounting evidence has highlighted the complex nature of the inflammatory microenvironment in these tumors. Methods  A review of the literature pertaining to inflammation, inflammatory molecular pathways, and immune-related therapeutic targets in VS was performed. Relevant studies published up to June 2020 were identified based on a literature search in the PubMed and MEDLINE databases and the findings were synthesized into a concise narrative review of the topic. Results  The VS microenvironment is characterized by a dense infiltrate of inflammatory cells, particularly macrophages. Significantly higher levels of immune cell infiltration are observed in growing versus static tumors, and there is a demonstrable interplay between inflammation and angiogenesis in growing VS. While further mechanistic studies are required to ascertain the exact role of inflammation in angiogenesis, tumor growth, and Schwann cell control, we are beginning to understand the key molecular pathways driving this inflammatory microenvironment, and how these processes can be monitored and targeted in vivo . Conclusion  Observational research has revealed a complex and heterogeneous tumor microenvironment in VS. The functional landscape and roles of macrophages and other immune cells in the VS inflammatory infiltrate are, however, yet to be established. The antiangiogenic drug bevacizumab has shown the efficacy of targeted molecular therapies in VS and there is hope that agents targeting another major component of the VS microenvironment, inflammation, will also find a place in their future management. Thieme. All rights reserved.

Entities:  

Keywords:  angiogenesis; antiangiogenic; bevacizumab; biomarkers; immunomodulation; immunotherapy; inflammation; tumor immunology; tumor-associated macrophages; vestibular schwannoma

Year:  2020        PMID: 35155063      PMCID: PMC8824628          DOI: 10.1055/s-0040-1716688

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  77 in total

1.  The natural history of vestibular schwannoma.

Authors:  Sven-Eric Stangerup; Per Caye-Thomasen; Mirko Tos; Jens Thomsen
Journal:  Otol Neurotol       Date:  2006-06       Impact factor: 2.311

2.  Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.

Authors:  Shiyang Wang; Benjamin Liechty; Seema Patel; Jeffrey S Weber; Travis J Hollmann; Matija Snuderl; Matthias A Karajannis
Journal:  J Neurooncol       Date:  2018-02-09       Impact factor: 4.130

3.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

4.  B7-H1 expression in vestibular schwannomas.

Authors:  David J Archibald; Brian A Neff; Stephen G Voss; Patrick L Splinter; Colin L W Driscoll; Michael J Link; Haidong Dong; Eugene D Kwon
Journal:  Otol Neurotol       Date:  2010-08       Impact factor: 2.311

5.  Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.

Authors:  S Ammoun; L Provenzano; L Zhou; M Barczyk; K Evans; D A Hilton; S Hafizi; C O Hanemann
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

Review 6.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

Authors:  Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2014-05-29       Impact factor: 13.506

7.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.

Authors:  B Barleon; S Sozzani; D Zhou; H A Weich; A Mantovani; D Marmé
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

8.  Predominance of M1 subtype among tumor-associated macrophages in phenotypically aggressive sporadic vestibular schwannoma.

Authors:  Avital Perry; Christopher S Graffeo; Lucas P Carlstrom; Aditya Raghunathan; Colin L W Driscoll; Brian A Neff; Matthew L Carlson; Ian F Parney; Michael J Link; Jamie J Van Gompel
Journal:  J Neurosurg       Date:  2019-10-04       Impact factor: 5.115

Review 9.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

10.  Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma.

Authors:  Daniel Lewis; Federico Roncaroli; Erjon Agushi; Dominic Mosses; Ricky Williams; Ka-Loh Li; Xiaoping Zhu; Rainer Hinz; Ross Atkinson; Andrea Wadeson; Sharon Hulme; Helen Mayers; Emma Stapleton; Simon K L Lloyd; Simon R Freeman; Scott A Rutherford; Charlotte Hammerbeck-Ward; D Gareth Evans; Omar Pathmanaban; Alan Jackson; Andrew T King; David J Coope
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.